Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TaiMed Biologics Inc. (4147.TWO)
Taipei, TW
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.50% | +0.00% | -8.27% | -4.73% | -26.56% | -19.36% | -36.57% | -53.66% | -21.04% | -76.78% | +3.24% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+0.2% Q1'26: -5.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+18.7% Q1'26: +166.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+6.3% Q1'26: +5.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-31.8% Q1'26: +1.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-7.5% ★ Q1'26: +0.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.6% ★ Q1'26: -4.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-11.84× Q1'26: 54.45× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.08M
est: 2.07M (+0.3%)
|
8.44M
est: 9.27M (-8.9%)
|
241.04M
est: 243.30M (-0.9%)
|
704.50M
est: 776.05M (-9.2%)
|
722.49M
est: 917.00M (-21.2%)
|
413.44M
est: 656.98M (-37.1%)
|
563.01M
est: 350.00M (+60.9%)
|
491.78M
est: 641.66M (-23.4%)
|
610.16M
est: 610.00M (+0.0%)
|
611.35M
est: 610.50M (+0.1%)
|
680.00M
680.00M – 680.00M
+11.4% YoY
|
| EBITDA |
-309.41M
est: -451.7K (-68,392.1%)
|
-541.43M
est: -2.02M (-26,677.6%)
|
-258.80M
est: -53.10M (-387.4%)
|
-485.76M
est: -169.36M (-186.8%)
|
-40.06M
est: -200.12M (+80.0%)
|
-307.45M
est: -143.38M (-114.4%)
|
-102.74M
est: -76.38M (-34.5%)
|
-25.23M
est: -141.66M (+82.2%)
|
-35.57M
est: -134.67M (+73.6%)
|
-41.66M
est: -134.78M (+69.1%)
|
-150.13M
-150.13M – -150.13M
-11.4% YoY
|
| EBIT |
-312.90M
est: -986.8K (-31,610.0%)
|
-545.22M
est: -4.42M (-12,244.9%)
|
-321.70M
est: -115.98M (-177.4%)
|
-578.30M
est: -369.94M (-56.3%)
|
-179.22M
est: -437.13M (+59.0%)
|
-463.49M
est: -313.18M (-48.0%)
|
-259.19M
est: -166.84M (-55.4%)
|
-180.00M
est: -314.90M (+42.8%)
|
-189.23M
est: -299.36M (+36.8%)
|
-194.65M
est: -299.61M (+35.0%)
|
-333.72M
-333.72M – -333.72M
-11.4% YoY
|
| Net Income |
-281.96M
est: -240.57M (-17.2%)
|
-524.55M
est: -695.87M (+24.6%)
|
-321.71M
est: -293.17M (-9.7%)
|
-579.01M
est: -469.08M (-23.4%)
|
-187.39M
est: -142.76M (-31.3%)
|
-478.38M
est: -245.86M (-94.6%)
|
-279.39M
est: -289.82M (+3.6%)
|
-194.81M
est: -116.92M (-66.6%)
|
-201.83M
est: -126.52M (-59.5%)
|
-167.78M
est: -138.90M (-20.8%)
|
-74.26M
-74.26M – -74.26M
+46.5% YoY
|
| SGA |
38.37M
est: 331.6K (+11,468.4%)
|
42.92M
est: 1.48M (+2,791.2%)
|
42.63M
est: 38.98M (+9.4%)
|
44.17M
est: 124.33M (-64.5%)
|
59.55M
est: 146.91M (-59.5%)
|
109.72M
est: 105.26M (+4.2%)
|
74.45M
est: 56.07M (+32.8%)
|
97.19M
est: 96.29M (+0.9%)
|
75.29M
est: 91.54M (-17.8%)
|
19.36M
est: 91.61M (-78.9%)
|
102.04M
102.04M – 102.04M
+11.4% YoY
|
| EPS |
-1.12
est: -0.90 (-24.9%)
|
-2.07
est: -2.59 (+20.2%)
|
-1.26
est: -1.09 (-15.3%)
|
-2.27
est: -1.75 (-29.8%)
|
-0.72
est: -0.53 (-35.3%)
|
-1.87
est: -0.92 (-104.0%)
|
-1.05
est: -1.07 (+2.3%)
|
-0.77
est: -0.43 (-81.1%)
|
-0.75
est: -0.46 (-63.0%)
|
-0.61
est: -0.51 (-20.8%)
|
-0.27
-0.27 – -0.27
+46.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.06M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 33.3K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 75.2K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 3.71M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 51.1K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 4.20M | 0.05% |
| 7 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 8.6K | 0.24% |
| 8 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 8.6K | 0.24% |
| 9 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 6.0K | 0.22% |
| 10 | Vanguard Total World Stock ETF VT | 0.00% | 184.9K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chen Yicheng | Accounting Supervisor | — | — |
| Chin-Ming Chang | President, Chief Executive Officer & Director | — | male |
| David D. | Scientific Co-Founder, Chief Scientific Advisor and Board Director | — | — |
| Ing-Wen Tsai | Co-Founder | — | — |
| Lan-Bo Chen | Co-Founder | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4147.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
